BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
Launched by CONMED CORPORATION · Aug 10, 2023
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a prospective, single blind, multi-center, randomized, controlled, pivotal clinical study investigating the treatment of full thickness tears of the rotator cuff. Tears must involve the supraspinatus and/or infraspinatus tendons and measure ≥ 2 cm and \< 5 cm. Subjects meeting the inclusion/exclusion criteria will be enrolled and will undergo either arthroscopic rotator cuff repair augmented with the BioBrace® Implant or arthroscopic rotator cuff repair alone. Clinical evaluations will be conducted at baseline (pre-operatively) and at 6 weeks, 3-, 6-, and 12-months post-operatively ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female 40 to 70 years old
- 2. Positive diagnostic imaging by MRI within 6 months of enrollment of the index shoulder indicating a full thickness rotator cuff tear (RCT):
- • 1. Tear of the supraspinatus and/or infraspinatus tendons
- • 2. Tear size ≥ 2 cm and \< 5 cm
- • 3. Chronic shoulder pain ≥ 3 months
- 4. Failed non-operative treatment of the index shoulder to include one or all of the following:
- • 1. Oral analgesics
- • 2. Nonsteroidal anti-inflammatory medications (NSAIDs)
- • 3. Corticosteroid injections
- • 4. Activity modifications
- • 5. Physical therapy or home-guided exercises
- • 5. Able to read and understand the study REB/IRB approved Informed Consent Form (ICF)
- • 6. Willing to be available to attend each protocol-required follow-up examination
- Intraoperative Inclusion Criteria:
- • 1. Full thickness tear of the supraspinatus and/or infraspinatus tendons
- • 2. Tear size ≥ 2 cm and \< 5 cm
- • 3. Able to reapproximate the tendons to cover \> 50% of the footprint on the greater tuberosity
- Exclusion Criteria:
- • 1. Previous surgery of the index shoulder one year prior to the study surgery excluding diagnostic arthroscopy
- • 2. Fatty infiltration of the index shoulder rotator cuff muscle ≥ Grade 3 (Goutallier Score)
- • 3. Major medical condition that could affect quality of life and influence the results of the study as determined by the Investigator
- • 4. Oral steroid use or steroid injection within 6 weeks prior to surgery
- • 5. Active smoker
- • 6. History of insulin-dependent diabetes
- • 7. Documented evidence of a history (e.g., liver testing) of drug/alcohol abuse within 12 months of enrollment
- • 8. Hypersensitivity to any investigational device materials including collagen of animal origin (bovine type-I), poly-L-lactic acid (PLLA) or polyethylene glycol (PEG)
- • 9. Presence of an implanted metallic device or other implants that would contraindicate acquisition or inhibit radiologist review of an MRI of the index shoulder
- • 10. History of claustrophobia that would prevent an MRI of the index shoulder
- • 11. Females of child-bearing potential who are either pregnant or breastfeeding or plan to become pregnant during the course of the study
- • 12. Currently participating, or plans to enroll in another clinical trial during this study that would affect the outcomes of this study as determined by the Investigator
- • 13. History of non-compliance with medical treatment or clinical trial participation
- • 14. The subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.), to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant with protocol required follow-up
- • 15. Any comorbidity or condition that renders the patient a poor surgical candidate as determined by the Investigator
- • 16. The subject is receiving prescription narcotic pain medication
- • 17. The subject currently has an acute infection in the area surrounding the surgical site
- • 18. Contralateral shoulder condition where rotator cuff repair is scheduled or to be scheduled over the course of this study
- • 19. The subject's condition represents a worker's compensation case
- Intraoperative Exclusion Criteria:
- • 1. Subject requires subscapularis repair other than a repair with a single anchor
About Conmed Corporation
ConMed Corporation is a leading global medical technology company dedicated to providing innovative solutions for minimally invasive surgical procedures and patient monitoring. With a strong emphasis on research and development, ConMed specializes in advanced surgical instruments, devices, and systems that enhance the safety and efficacy of healthcare delivery. The company is committed to improving patient outcomes and supporting healthcare professionals through its extensive portfolio of products and clinical trials aimed at addressing the evolving needs of the medical community. ConMed's focus on quality, innovation, and collaboration positions it as a trusted partner in the advancement of medical technology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported